Enbrel (etanercept)
Product · Pharmaceutical / drug · HR & recruiting by Amgen
A biologic therapy for chronic inflammatory conditions in adults and children.
Enbrel is a prescription biologic medicine for adults and children with certain inflammatory diseases, including rheumatoid arthritis and plaque psoriasis. It is used to reduce symptoms and inhibit structural damage by targeting tumor necrosis factor.
- Languages
- English
- Prescription
- Prescription Only
- Active Ingredient
- etanercept
- Therapeutic Class
- TNF Blocker
- Administration Formats
- Prefilled Syringe, Vial, and other patient-use formats
- Minimum Patient Age (JIA)
- 2 years
- Indicated for moderately to severely active rheumatoid arthritis in adults
- Approved for pediatric use in patients ages 2 and older with polyarticular JIA
- Used for chronic moderate to severe plaque psoriasis in adults
- Indicated for active psoriatic arthritis and ankylosing spondylitis
Overview
Enbrel (etanercept) is a biologic medicine developed by Amgen for the treatment of various chronic inflammatory conditions. It is indicated for adult patients with moderate to severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and chronic moderate to severe plaque psoriasis. The medication is also approved for pediatric use in patients aged 2 and older with moderately to severely active polyarticular juvenile idiopathic arthritis. Enbrel works by inhibiting tumor necrosis factor (TNF) to manage symptoms and, in some cases, inhibit the progression of structural damage. It is available in several administration formats, including prefilled syringes, and is supported by detailed patient instructions for use.
Adult Inflammatory Conditions
- Rheumatoid Arthritis Treatment: The medication is indicated for reducing signs and symptoms, inducing major clinical response, and inhibiting the progression of structural damage in adults with moderately to severely active rheumatoid arthritis.
- Psoriatic Arthritis Management: It is used for reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in patients with psoriatic arthritis.
- Ankylosing Spondylitis Relief: The drug is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.
Pediatric Indications
- Juvenile Idiopathic Arthritis: Enbrel is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients ages 2 and older.
Dermatological Use
- Plaque Psoriasis Therapy: The treatment is indicated for adults with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Use cases
- Adults with rheumatoid arthritis use Enbrel to reduce signs and symptoms and induce clinical response.
- Patients with psoriatic arthritis use the medication to improve physical function and inhibit structural damage progression.
- Children aged 2 and older with polyarticular juvenile idiopathic arthritis receive treatment to manage active disease symptoms.
- Adults with moderate to severe plaque psoriasis use Enbrel when they are candidates for systemic therapy.
Specifications
- Indications
- Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Polyarticular Juvenile Idiopathic Arthritis
- Prescription
- Prescription Only
- Active Ingredient
- etanercept
- Therapeutic Class
- TNF Blocker
- Administration Formats
- Prefilled Syringe, Vial, and other patient-use formats
- Minimum Patient Age (JIA)
- 2 years
How it works
- Prescription and Diagnosis: A healthcare provider determines if the patient has one of the indicated inflammatory conditions and issues a prescription.
- Delivery and Instructions: Patients receive the medication in their prescribed form, such as prefilled syringes, along with detailed instructions for use.
- Administration: The medication is administered according to the patient instructions for use provided with the specific delivery device.
Added by AntSpace from public sources (amgen.com).